A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs MK 8504 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Sep 2017 Last checked against ClinicalTrials.gov record.
- 13 Sep 2017 Status changed from not yet recruiting to recruiting.
- 04 Sep 2017 Planned End Date changed from 28 Feb 2018 to 25 May 2018.